Vir Biotechnology, Inc. — Director's Dealing 2020

Sep 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2020-09-16

Reporting Person: Pang Phillip (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-09-16	Common Stock	M	9720	$1.575	Acquired	39497	Direct
2020-09-16	Common Stock	M	465	$1.53	Acquired	39962	Direct
2020-09-16	Common Stock	M	2315	$5.175	Acquired	42277	Direct
2020-09-16	Common Stock	S	7500	$31.8804	Disposed	34777	Direct
2020-09-16	Common Stock	S	5000	$31.9182	Disposed	29777	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-09-16	Employee Stock Option (Right to Buy)	$1.575	M	9720	Disposed	2028-07-19	Common Stock (9720)	Direct
2020-09-16	Employee Stock Option (Right to Buy)	$1.53	M	465	Disposed	2028-04-27	Common Stock (465)	Direct
2020-09-16	Employee Stock Option (Right to Buy)	$5.175	M	2315	Disposed	2029-03-11	Common Stock (2315)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.

F2: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

F3: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

F4: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.